Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls' drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life.
This report contains market size and forecasts of Postmenopausal Vaginal Atrophy Therapeutics in Global, including the following market information:
Global Postmenopausal Vaginal Atrophy Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Postmenopausal Vaginal Atrophy Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Estrogen-based Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Postmenopausal Vaginal Atrophy Therapeutics include Endoceutics, Accord Healthcare, Pfizer, Novo Nordisk, Teva Pharmaceuticals, Shionogi, Bionovo, QuatRx Pharmaceutical Company and Bayer AG and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Postmenopausal Vaginal Atrophy Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Postmenopausal Vaginal Atrophy Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Postmenopausal Vaginal Atrophy Therapeutics Market Segment Percentages, by Type, 2021 (%)
Estrogen-based Drugs
Non-estrogen-based Drugs
Global Postmenopausal Vaginal Atrophy Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Postmenopausal Vaginal Atrophy Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospital
Specialist Clinic
Global Postmenopausal Vaginal Atrophy Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Postmenopausal Vaginal Atrophy Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Postmenopausal Vaginal Atrophy Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Postmenopausal Vaginal Atrophy Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Endoceutics
Accord Healthcare
Pfizer
Novo Nordisk
Teva Pharmaceuticals
Shionogi
Bionovo
QuatRx Pharmaceutical Company
Bayer AG
TherapeuticsMD